28 April 2017

Arix Bioscience plc - Maiden Annual Results 2017

 

London, UK, 28 April 2017: Arix Bioscience plc (LSE:ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, today announces its maiden results for the period ended 31 December 2016.

The following financial statements refer to the period in which Arix Bioscience was a private company, prior to its initial public offering on the Main Market of the London Stock Exchange on 17 February 2017.

Corporate highlights

Company launch with the goal of generating value from the development and commercialisation of innovative technologies and discoveries

Formation of an internationally recognised leadership team including Jon Peacock, Sir Chris Evans and Joe Anderson

£52m private fundraise at launch to support early expansion phase

Partnerships agreed with research accelerators, BioMotiv in the US and the Max Planck Lead

Discovery Centre in Europe, and privileged relationships with leading academic centres, providing a constant, renewable source of access to opportunities

Acquisition of Arthurian Life Sciences, the investment manager of The Wales Life Sciences Investment Fund

Acquisition of direct interests in: Autolus, Artios Pharma, Depixus, OptiKira and Verona Pharma plc

Post-period highlights

Oversubscribed IPO on the Main Market of the London Stock Exchange, raising £112 million of new proceeds

Strategic partnerships signed with UCB Pharma and Takeda, to include participation in sourcing, screening, due diligence and joint business building

“In its first year, Arix has established itself with an innovative permanent capital model which seeks to create benefit for patients and value for shareholders by identifying the most dynamic technologies and businesses in healthcare and life sciences internationally. Arix is led by some of the most respected business builders in the industry, both in the UK and the US, with proven records of creating value. We now look ahead to a formative 2017, our first year as a public company following the successful IPO. We have a vigorous deal pipeline and are encouraged by the negotiations which are underway. We look forward to translating these opportunities into the announcement of significant new deals in the year ahead.”

Dr Joe Anderson

Chief Executive Officer of Arix Bioscience

In compliance with Listing Rule 9.6.3, the following documents have today been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/NSM:

Annual Report and Accounts for the period ended 31 December 2016

Notice of 2017 Annual General Meeting

Printed copies of these documents together with the Form of Proxy will be posted to shareholders shortly. Copies will also be available shortly on the Investor Relations section of the Company's website at www.arixbioscience.com

The 2017 Annual General Meeting will be held at the offices of Brown Rudnick, 8 Clifford Street, London W1S 2LQ on 5 June 2017 at 2pm.

For more information, please contact:

Arix Bioscience plc
Joe Anderson, CEO
+44 (0) 20 7290 1052

Consilium Strategic Communications
Mary-Jane Elliott, Jessica Hodgson, Ivar Milligan
+44 (0)20 3709 5700
arix@consilium-comms.com

About Arix Bioscience plc

Arix Bioscience plc is a global healthcare and life science company supporting medical innovation. Headquartered in London and with an office in New York, Arix Bioscience sources, finances and builds world class healthcare and life science businesses addressing medical innovation at all stages of development. Operations are supported by privileged access to breakthrough academic science and strategic relationships with leading research accelerators and global pharmaceutical companies.

Arix Bioscience plc is listed on the Main Market of the London Stock Exchange.

For further information, please visit www.arixbioscience.com


Back to previous page